In response, CMS has proposed a reinterpretation of the statutory exclusion, distinguishing between drugs used for weight loss and those used for the treatment of obesity. This shift would allow Part D and state Medicaid coverage for anti-obesity medications (AOMs) prescribed specifically for obesity
Its important to consider potential interactions that could impact metabolism and insulin response when using these two together
Then, you can throw away the pen or used needle and syringe in a sharps disposal container to prevent someone else from accidentally getting injured
however, absorption-based interactions are theoretically possible due to tirzepatide's effect on gastric emptying
And then the two new ones that everybody's talking about is Wegovywhich is the sister drug to Ozempic, an injectable GLP-1 agonist, and the most recent one to hit the airwaves in FDA approval is Zepbound, which is the sister drug to Mounjaro, and that one's a GLP and GIP medication, but also an injectable